Indeed SARC028, the first Phase II clinical study of 80 patients based on the administration of Pembrolizumab, an anti-PD-1 antibody to patients with advanced sarcomas has already provided results [170], while a HER2 s-generation CAR-T cell approach in patients with HER2+ OS and EWS unlighted the feasibility and safety of this treatment in patients with recurrent or refractory sarcomas [169]. This evidence concerns the gene PDCD1 and sarcoma.